Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 7/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18424056 | 0.91 | NAMPT (0.41) | GPR119CYP11B2NAMPTGPR183ACACB | |
| SCHEMBL25657234 | 0.86 | GPR119 (0.40) | GPR119HTTNR1H2 | |
| SCHEMBL18425705 | 0.85 | GPR119 (0.44) | GPR119 | |
| SCHEMBL25174705 | 0.81 | HTT (0.36) | HTT | |
| SCHEMBL25657238 | 0.77 | GPR183 (0.33) | GPR119CYP11B2NAMPTNR1H2GPR183 | |
| SCHEMBL18465709 | 0.77 | HSD11B1 (0.37) | GPR119HTTNR1H2 | |
| SCHEMBL27153102 | 0.76 | GPR119 (0.41) | GPR119NAMPTACACB | |
| SCHEMBL1394450 | 0.74 | USP2 (0.52) | GPR119CYP11B2NR1H2GPR183ACACB | |
| SCHEMBL18465824 | 0.74 | GPR119 (0.40) | GPR119NR1H2 | |
| SCHEMBL29161085 | 0.73 | USP2 (0.42) | GPR119CYP11B2NR1H2GPR183ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147859-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230147859-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147859-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC2 | GPR119 2091/4885CYP11B2 2566/4885NAMPT 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.